Background and Purpose
Pneumoconiosis, especially silicosis has emerged as a prominent
occupational disease with remarkable global implications with no
definitive cure available. While pirfenidone and nintedanib have been
approved in treating idiopathic pulmonary fibrosis, their potential
efficacy as anti-fibrotic agents in advanced silicosis warrants further
investigation. Thus, we aimed to assess the individual and combined
effects of pirfenidone and nintedanib in treating advanced silicosis
mice and further elucidate the underlying mechanisms involved in their
therapeutic actions.